Comprehensive Approach in Managing Hypertriglyceridemia: Integrating Pharmacological and Non-Pharmacological Strategies

Abstract

In many instances, hypertriglyceridemia is multifactorial, caused by a combination of genetic variables and other conditions that result in increased synthesis or impaired clearance of triglyceride-rich lipoproteins (TRLPs). Triglyceride (TG) levels that are significantly elevated increase the risk of developing pancreatitis and must be reduced with medication and lifestyle modifications in addition to an analysis of the underlying cause. Even though statin medication has improved the results of atherosclerotic cardiovascular disease (ASCVD), there is still a risk. Recent studies on the outcomes of cardiovascular disease when triglyceride-lowering medications are used suggest that, while a net benefit is likely present, both relative and absolute risk reductions appear modest in comparison to the benefit of lowering low-density lipoprotein cholesterol levels with treatment. Numerous studies have demonstrated that mild to moderate hypertriglyceridemia (HTG) is an independent risk factor for cardiovascular disease (CVD) in this context of residual atherosclerotic cardiovascular disease risk; however, the data do not provide conclusive proof that the risk of CVD decreases with the treatment of hypertriglyceridemia.